Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Phathom Pharmaceuticals, Inc. Director's Dealing 2021

Aug 18, 2021

32407_dirs_2021-08-18_61dc8dc5-2a2e-47bc-b8cc-1b8c6023eea1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2021-08-16

Reporting Person: Socks David A (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-16 Common Stock S 4209 $30.4704 Disposed 1261137 Indirect
2021-08-16 Common Stock S 13791 $31.4907 Disposed 1247346 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 103.49 Indirect

Footnotes

F1: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.98. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The total number of outstanding shares reflects an increase of 4,401 shares to correct an arithmetic error in the total number of shares initially reported on his Form 4 filed on November 9, 2020.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.80.The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.